Cyclerion Therapeutics clinical trials
Formerly part of Ironwood Pharmaceuticals, Inc., Apr 1, 2019 · source ↗
The registry lists 11 studies whose lead sponsor is Cyclerion Therapeutics. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 21, 2023.
Before and after it left Ironwood Pharmaceuticals, Inc.
- First submitted before Cyclerion Therapeutics left Ironwood Pharmaceuticals, Inc.
- 11
- First submitted after Cyclerion Therapeutics left Ironwood Pharmaceuticals, Inc.
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Cyclerion Therapeutics11 studies
Something wrong with this grouping? Tell us on the Ironwood Pharmaceuticals, Inc. page.
Studies
Recruiting first, then most recently updated. Showing 11 of 11. All Ironwood Pharmaceuticals, Inc. studies →
- A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)CompletedNCT03285178Phase 2
Sponsor listed in the registry: Cyclerion Therapeutics · First submitted before Cyclerion Therapeutics left Ironwood Pharmaceuticals, Inc.
- Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II AchalasiaTerminatedNCT02931565Phase 2
Sponsor listed in the registry: Cyclerion Therapeutics · First submitted before Cyclerion Therapeutics left Ironwood Pharmaceuticals, Inc.
- Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and HypertensionCompletedNCT03091920Phase 2
Sponsor listed in the registry: Cyclerion Therapeutics · First submitted before Cyclerion Therapeutics left Ironwood Pharmaceuticals, Inc.
- A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and HypertensionCompletedNCT02906579Phase 2
Sponsor listed in the registry: Cyclerion Therapeutics · First submitted before Cyclerion Therapeutics left Ironwood Pharmaceuticals, Inc.
- A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy VolunteersCompletedNCT03892499Phase 1
Sponsor listed in the registry: Cyclerion Therapeutics · First submitted before Cyclerion Therapeutics left Ironwood Pharmaceuticals, Inc.
- A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Praliciguat in Healthy Male VolunteersCompletedNCT03818295Phase 1
Sponsor listed in the registry: Cyclerion Therapeutics · First submitted before Cyclerion Therapeutics left Ironwood Pharmaceuticals, Inc.
- A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Olinciguat in Healthy Male VolunteersCompletedNCT03795519Phase 1
Sponsor listed in the registry: Cyclerion Therapeutics · First submitted before Cyclerion Therapeutics left Ironwood Pharmaceuticals, Inc.
- Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy VolunteersCompletedNCT02572349Phase 1
Sponsor listed in the registry: Cyclerion Therapeutics · First submitted before Cyclerion Therapeutics left Ironwood Pharmaceuticals, Inc.
- A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of Praliciguat (IW-1973) in Healthy VolunteersCompletedNCT03499106Phase 1
Sponsor listed in the registry: Cyclerion Therapeutics · First submitted before Cyclerion Therapeutics left Ironwood Pharmaceuticals, Inc.
- Trial of IW-1973 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy VolunteersCompletedNCT02616861Phase 1
Sponsor listed in the registry: Cyclerion Therapeutics · First submitted before Cyclerion Therapeutics left Ironwood Pharmaceuticals, Inc.
- A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy SubjectsCompletedNCT02792998Phase 1
Sponsor listed in the registry: Cyclerion Therapeutics · First submitted before Cyclerion Therapeutics left Ironwood Pharmaceuticals, Inc.